-SEC Filing
Sagimet Announces Oral Presentation Of Data From The Phase 2b FASCINATE-2 Study Of Denifanstat In MASH At EASL International Liver Congress 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today